Showing 4151-4160 of 5771 results for "".
- Lumenis Named “Best Overall Medical Device Company” in 2021 MedTech Breakthrough Awardshttps://modernod.com/news/lumenis-named-best-overall-medical-device-company-in-2021-medtech-breakthrough-awards/2479201/Lumenis announced that it has been selected as the “Best Overall Medical Device Company” in the MedTech Breakthrough Awards. MedTech Breakthrough is an independent market intelligence organization that honors excellence and recognizes the top companies, technologies and products in the global he
- Euclid Systems Launches New Euclid MAX Ortho-K Lenshttps://modernod.com/news/euclid-systems-launches-new-euclid-max-ortho-k-lens/2479200/Euclid Systems announced the United States launch of the overnight orthokeratology lens Euclid MAX. Used in children and adult patients with progressive myopia, but especially children, Ortho-K contact lenses gently reshape the cornea to manage myopia while the patient sleeps. “Euclid MAX
- Modernizing Medicine Releases Enhanced Ophthalmic Image Management to Improve Clinical Workflowhttps://modernod.com/news/modernizing-medicine-releases-enhanced-ophthalmic-image-management-to-improve-clinical-workflow/2479198/Modernizing Medicine announced it has released the latest version of ophthalmic Image Management aimed at helping ophthalmologists save time and deliver efficiency associated with diagnostic imaging workflows. Many ophthalmologists benefit from having an all-in-one solution that bridges da
- Ocuphire Completes Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Combination with Low-Dose Pilocarpine for Treatment of Presbyopiahttps://modernod.com/news/ocuphire-completes-enrollment-in-vega-1-phase-2-trial-investigating-nyxol-in-combination-with-low-dose-pilocarpine-for-treatment-of-presbyopia/2479197/Ocuphire Pharma announced that it has completed enrollment in the VEGA-1 phase 2 clinical trial (
- RVL Pharmaceuticals Upneeq Wins 2021 MedTech Breakthrough Awardhttps://modernod.com/news/rvl-pharmaceuticals-upneeq-wins-2021-medtech-breakthrough-award/2479196/RVL Pharmaceuticals, a subsidiary of Osmotica Pharmaceuticals, announced that its ptosis drug Upneeq (oxymetazoline hydrochloride ophthalmic solution), 0.1% has been selected as the winner of the “Best New Technology Solution for Drug Delivery” award in the fifth annual MedTech Breakthrough Award
- Heine OMEGA 600 Indirect Ophthalmoscope Launched In the UKhttps://modernod.com/news/heine-omega-600-indirect-ophthalmoscope-launched-in-the-uk/2479195/John Weiss & Son has announced the launch of the Heine Omega 600 Indirect Ophthalmoscope in the UK. The new OMEGA 600 enables the clinician to provide a more accurate diagnosis. It features superior non-reflective glass optics, sharp images and reliable, natural colors. Stereoscopic ad
- New National Eye Institute Data Shows AREDS2 Nutrient Formula Continues To Reduce The Risk Of Moderate To Advanced AMD Progressionhttps://modernod.com/news/new-national-eye-institute-data-shows-areds2-nutrient-formula-continues-to-reduce-the-risk-of-moderate-to-advanced-amd-progression/2479193/Bausch + Lomb announced new data from the National Eye Institute (NEI) 10-Year Follow-on Study Results of the Age-Related Eye Disease Study 2 (AREDS2), which reaffirms the clinical outcomes of the AREDS2 study. Based on this data, the NEI continues to recommend a specific nutrient formula to help
- Bio-Tissue to Present Webinar in 3-D Showcasing New Treatment Regimen to Diagnose and Treat Mechanical Dry Eyehttps://modernod.com/news/bio-tissue-to-present-webinar-in-3-d-showcasing-new-treatment-regimen-to-diagnose-and-treat-mechanical-dry-eye/2479188/Bio-Tissue announced today that it will present a special 3-D webinar on Wednesday, May 19, 2021, from 8:30 pm to 9:30 pm EDT, hosted by Neel Desai, MD, who will demonstrate his novel surgical technique known as Reservoir Restoration to treat Mechanical Dry Eye (MDE). He will also discuss how to
- Belkin Laser Completes Enrollment of its GLAUrious Pivotal Trial for Glaucoma Laser Treatment in Secondshttps://modernod.com/news/belkin-laser-completes-enrollment-of-its-glaurious-pivotal-trial-for-glaucoma-laser-treatment-in-seconds-2/2479186/Belkin Laser announced that it has completed enrollment in its GLAUrious randomized controlled trial. In this confirmatory, prospective, noninferiority, observer masked RCT a total of 192 patients were randomized across two arms, SLT and DSLT. Six-month follow up for primary endpoint is expected
- Rayner’s RayOne Aspheric preloaded IOL launches in Chinahttps://modernod.com/news/rayners-rayone-aspheric-preloaded-iol-launches-in-china/2479183/Rayner announced that its RayOne Aspheric fully preloaded IOL injection system has been approved by the Chinese regulator, National Medical Products Administration (NMPA), and is now available for commercial use in China. The NMPA granted regulatory approval and sale of the 6.0 mm RayOne A